Abstract:The process of developing new drugs is widely acknowledged as being time-intensive and requiring substantial financial investment. Despite ongoing efforts to reduce time and expenses in drug development, ensuring medication safety remains an urgent problem. One of the major problems involved in drug development is hepatotoxicity, specifically known as drug-induced liver injury (DILI). The popularity of new drugs often poses a significant barrier during development and frequently leads to their recall after launch. In silico methods have many advantages compared with traditional in vivo and in vitro assays. To establish a more precise and reliable prediction model, it is necessary to utilize an extensive and high-quality database consisting of information on drug molecule properties and structural patterns. In addition, we should also carefully select appropriate molecular descriptors that can be used to accurately depict compound characteristics. The aim of this study was to conduct a comprehensive investigation into the prediction of DILI. First, we conducted a comparative analysis of the physicochemical properties of extensively well-prepared DILI-positive and DILI-negative compounds. Then, we used classic substructure dissection methods to identify structural pattern differences between these two different types of chemical molecules. These findings indicate that it is not feasible to establish property or substructure-based rules for distinguishing between DILI-positive and DILI-negative compounds. Finally, we developed quantitative classification models for predicting DILI using the naïve Bayes classifier (NBC) and recursive partitioning (RP) machine learning techniques. The optimal DILI prediction model was obtained using NBC, which combines 21 physicochemical properties, the VolSurf descriptors and the LCFP_10 fingerprint set. This model achieved a global accuracy (GA) of 0.855 and an area under the curve (AUC) of 0.704 for the training set, while the corresponding values were 0.619 and 0.674 for the test set, respectively. Moreover, indicative substructural fragments favorable or unfavorable for DILI were identified from the best naïve Bayesian classification model. These findings may help prioritize lead compounds in the early stage of drug development pipelines.

Identification of Drug-Induced Liver Injury Biomarkers from Multiple Microarrays Based on Machine Learning and Bioinformatics Analysis

Metabolomics and Cytokine Analysis for Identification of Severe Drug-Induced Liver Injury.

A serum metabonomics study on drug induced liver injury by UPLC coupled with Q-TOF mass spectrometry

Gene Expression Data Based Deep Learning Model for Accurate Prediction of Drug-Induced Liver Injury in Advance

Machine-Learning Prediction of Oral Drug-Induced Liver Injury (DILI) via Multiple Features and Endpoints

Deep Learning Algorithm Based on Molecular Fingerprint for Prediction of Drug‐Induced Liver Injury

Identification of Effective Diagnostic Biomarker and Immune Cell Infiltration Characteristics in Acute Liver Failure by Integrating Bioinformatics Analysis and Machine-Learning Strategies

Progress in the biomarker discovery for drug-induced liver injury]

MicroRNAs in Drug-induced Liver Injury.

Deep Learning for Drug-Induced Liver Injury.

Insights into Mechanisms and Severity of Drug-Induced Liver Injury Via Computational Systems Toxicology Approach.

Predicting drug-induced liver injury using ensemble learning methods and molecular fingerprints.

Deep Learning on High-Throughput Transcriptomics to Predict Drug-Induced Liver Injury

An entropy weight method to integrate big omics and mechanistically evaluate DILI

Prediction of Drug-Induced Liver Injury: From Molecular Physicochemical Properties and Scaffold Architectures to Machine Learning Approaches

Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort

In Silico Prediction of Drug‐induced Liver Injury with a Complementary Integration Strategy Based on Hybrid Representation

DeepDILI: Deep Learning-Powered Drug-Induced Liver Injury Prediction Using Model-Level Representation.

The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury

Novel Clinical Biomarkers for Drug-Induced Liver Injury.

Combined analysis of 16S rDNA sequencing and metabolomics to find biomarkers of drug-induced liver injury